|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired T790M mutations account for 50%-60% of tyrosine kinase inhibitor (TKI)-resistant mechanisms in <i>EGFR</i> mutation-positive (m+) non-small-cell lung cancer (NSCLC) patients, and re-biopsy is recommended to detect these mutations.
|
30464499 |
2018 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired T790M fraction of EGFR-mutated NSCLC is linked to different generations of prior EGFR TKI use and the later efficacy of osimertinib.
|
31346928 |
2019 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
|
26749488 |
2016 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
|
25939061 |
2015 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring <i>EGFR</i> mutations.
|
28978102 |
2017 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
|
22891040 |
2012 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additional challenges in this patient population, such as the upfront efficacy of osimertinib, validation of T790M in liquid biopsies as a dynamic predictive marker of efficacy, along with combination with immune checkpoint inhibitors are being explored, representing an extraordinary time of development for EGFR-mutant NSCLC.
|
29462255 |
2018 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, osimertinib has good efficacy and a manageable safety profile in Japanese patients with NSCLC who had acquired resistance due to the T790M mutation.
|
31265163 |
2019 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, the EGFR T790M mutation was found in 46.7% (7/15) of the patients with EGFR-TKI-resistant NSCLC, suggesting that the NGS-based ctDNA assay might be an optional method to monitor EGFR-TKI resistance and to discover mechanisms of drug resistance.
|
29097733 |
2017 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Afatinib followed by osimertinib may provide better outcomes for T790M-positive NSCLC than 1st-G EGFR-TKIs.
|
31262922 |
2019 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Afatinib is a novel TKI that is efficacious and well tolerated in patients with NSCLC associated with activating EGFR mutations, including cases involving the T790M resistance mutation.
|
25349236 |
2014 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
After screening 598 herbal and natural compounds, we found curcumin could inhibit cell proliferation in different gefitinib-resistant NSCLC cell lines; concentration-dependently down-regulate EGFR phosphorylation through promoting EGFR degradation in NSCLC cell lines with wild-type EGFR or T790M EGFR.
|
21858220 |
2011 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although clinical trials of AURA series illustrated that non-small cell lung cancer (NSCLC) with <i>EGFR</i> T790M mutation can benefit from osimertinib, only five LSCC patients were enrolled in total; moreover, the efficacy for LSCC was not shown in the results.
|
31183356 |
2019 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although epidermal growth factor receptor (EGFR) kinase inhibitors are effective for the treatment of non-small cell lung cancer (NSCLC), the emergence of mutations resistant to these inhibitors, such as T790M, has become a clinical problem.
|
19459856 |
2009 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been introduced for the treatment of non-small cell lung cancer (NSCLC), the emergence of secondary T790M mutation in EGFR or amplification of the Met proto-oncogene restrain the clinical success of EGFR-TKIs.
|
25117641 |
2014 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790M/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.
|
29290257 |
2018 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) can overcome T790M-mediated resistance in non-small-cell lung cancer (NSCLC), rebiopsy to confirm T790M status is occasionally difficult.
|
27145431 |
2016 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among the third-generation <i>EGFR</i> TKIs, osimertinib is today the only drug approved by the Food and Drug Administration and the European Medicines Agency to treat metastatic <i>EGFR</i> T790M NSCLC patients who have progressed on or after <i>EGFR</i> TKI therapy.
|
28149837 |
2016 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
An MR was detected in 15% of NSCLC patients with T790M.
|
30735003 |
2019 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Apatinib significantly potentiated the antitumour effect of gefitinib in NSCLC with T790M-related EGFR-TKI resistance both in vivo and vitro.
|
28822888 |
2017 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
AQTGTGKT peptide decreased tumorigenic potentials of PC-9/ER and H1975 cells, non-small cell lung cancer (NSCLC) cells with EGFR mutation (L885R/T790M), by inhibiting autophagic fluxand inhibiting the binding of CAGE to Beclin1.
|
30619741 |
2018 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
ASP8273 is a third-generation EGFR TKI with antitumor activity in preclinical models of EGFR-mutant lung cancer that targets mutant EGFR, including <i>EGFR</i> T790M.<b>Experimental Design:</b> In this multicohort, phase I study (NCT02113813), escalating doses of ASP8273 (25-500 mg) were administered once daily to non-small cell lung cancer (NSCLC) patients with disease progression after prior treatment with an EGFR TKI.
|
28954786 |
2017 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancer.
|
31339357 |
2019 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
AT-101 enhances gefitinib sensitivity in NSCLC with EGFR T790M mutations.
|
27431492 |
2016 |
|
rs121434569
|
|
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Avitinib (AC0010) is a mutant-selective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), designed to be a targeted therapeutic agent for non-small cell lung cancer (NSCLC) patients harboring EGFR active and T790M resistant mutations.
|
28285073 |
2017 |